An interventional study of SELUTION SLR 014 DEB and Standard of Care in Coronary Restenosis, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 48 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies in Coronary Restenosis with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Coronary Restenosis · United States.
Among the 30 studies in Coronary Restenosis with a site in United States, this one is the 11th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2020, is one of 7 with no phase, and was the 28th registered.
107 studies on the registry are indexed under Coronary Restenosis; 10 are open to participants now.
Browse Coronary Restenosis studies →1 of the 30 studies in Coronary Restenosis with a site in United States is open now. Recruiting first, the newest first:
Abbott Medical Devices · Sites in United States, Australia, Austria and 11 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 8 Coronary Restenosis studies recruiting now, 7 set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 6 · Phase 4 5
First in 2003; this study’s year is marked. 2 started in 2020.
This study's enrollment of 418 is above the median of 242 across 69 interventional studies indexed under Coronary Restenosis.
Median enrollment 480 across the 19 interventional studies, 1,501 across the 10 observational. Of the 27 that completed or were terminated, 13 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 30 have an industry lead sponsor. The 10 most frequent:
M.A. Med Alliance S.A. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
M.A. Med Alliance S.A. has 1 study filed under Coronary Restenosis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 30 studies in Coronary Restenosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial.
Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for In-stent Restenosis (ISR) will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or Standard of Care (SOC) to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or Balloon Angioplasty (BA). A maximum of 20% of patients randomized to SOC will be treated with BA.
The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB in all patients.
Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial will enroll up to 418 randomized subjects (including up to 60 subjects in an angiographic and optical coherence tomography [OCT] sub-study) at up to 80 sites in the United States (US), Canada, Brazil, and Europe (EU). A minimum of 50% of the subjects will be enrolled in the US.
Subjects with previous bare-metal stent (BMS) or Drug-Eluting Stent (DES) and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA.
The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR 014 DEB group.
A subset of up to 60 subjects will be enrolled in the angiographic and OCT sub-study and undergo planned angiographic and OCT follow-up within 30 days after completion of the 12-month primary endpoint clinical follow-up/assessment.
Clinical Inclusion Criteria:
Angiographic Inclusion Criteria
Clinical Exclusion Criteria:
Angiographic Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).
Device: SELUTION SLR 014 DEB
Plain Old Balloon Angioplasty (POBA) or FDA-approved commercially available -limus eluting Drug-Eluting Stent (DES)
Device: Standard of Care
The SELUTION Sustained Limus Release (SLR)™ 014 drug-eluting balloon (DEB) catheter is a combination product consisting of a standard percutaneous transluminal angioplasty (PTA) balloon catheter coated with a drug (Sirolimus).
POBA or FDA-approved commercially available -limus eluting DES
Number of Participants With Target Lesion Failure (TLF)
TLF is defined as all cardiac death, target vessel myocardial infarction (MI) or clinically driven Target Lesion Revascularization (TLR). MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.
Time frame: 12 months post-index procedure
Device Success
Time frame: Index Procedure
Lesion Success
Time frame: Index Procedure
Procedure Success
Time frame: Index Procedure
Composite Safety Endpoint
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Clinically Driven Target Vessel Revascularization (TVR), All TVR, Non-TVR
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
TLF
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Target Vessel Failure (TVF)
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Net Adverse Clinical Events
Time frame: Prior to discharge, at 1, 6, and 12 months
Binary Angiographic Restenosis
Time frame: 12 months
In-stent Percent Diameter Stenosis
Time frame: 12 months
In-segment Percent Diameter Stenosis
Time frame: 12 months
In-stent Late Lumen Loss (LLL)
Time frame: 12 months
In-segment LLL
Time frame: 12 months
In-stent Minimum Lumen Diameter (MLD)
Time frame: 12 months
In-segment MLD
Time frame: 12 months
Optical Coherence Tomography (OCT) Assessment of Neointimal Hyperplasia, Neo-atherosclerosis, and Stent Malapposition
Time frame: 12 months
TLF
SELUTION SLR 014 DEB versus DES among participants with one previous layer of stent
Time frame: 12 months
Clinically-driven TLR
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
All-cause Mortality
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Cardiovascular Mortality
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
MI
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
All TLR
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Stent Thrombosis
Time frame: Prior to discharge, at 1, 6, and 12 months and annually thereafter through 5 years follow-up
Bleeding
Time frame: Prior to discharge, at 1, 6, and 12 months
Cardiac Biomarker Elevations
Time frame: Peri-Procedural
| Milestone | SELUTION SLR 014 DEB | Standard Of Care |
|---|---|---|
| Started | 210 | 208 |
| Completed | 197 | 199 |
| Not completed | 13 | 9 |
| Withdrew: Withdrawal by subject | 1 | 1 |
| Withdrew: Death | 9 | 5 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Site closing & voluntarily withdrawing and withdrawal with continued emr and public records review | 2 | 3 |
TLF is defined as all cardiac death, target vessel myocardial infarction (MI) or clinically driven Target Lesion Revascularization (TLR). MI includes spontaneous (Type 1) MI using the 4th Universal Definition of Myocardial Infarction (UDMI) and peri-procedural MI using the Society for Cardiac Angiography and Intervention (SCAI) definition.
| Participants | SELUTION SLR 014 DEB | Standard Of Care |
|---|---|---|
| Number of Participants With Target Lesion Failure (TLF) | 32 | 28 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
SELUTION SLR 014 DEB versus DES among participants with one previous layer of stent
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Up to 365 days post procedure. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SELUTION SLR 014 DEB | 9/210 (4.3%) | 78/210 (37.1%) | 27/210 (12.9%) |
| Standard Of Care | 5/208 (2.4%) | 91/208 (43.8%) | 23/208 (11.1%) |
| Event | SELUTION SLR 014 DEB | Standard Of Care |
|---|---|---|
| Angina PectorisCardiac disorders | 12/210 | 17/208 |
| Acute Myocardial InfarctionCardiac disorders | 15/210 | 11/208 |
| Angina unstableCardiac disorders | 8/210 | 4/208 |
| Atrial FibrillationCardiac disorders | 8/210 | 3/208 |
| Chest painGeneral disorders | 3/210 | 7/208 |
| Arteriosclerosis coronary arteryCardiac disorders | 2/210 | 5/208 |
| Ventricular tachycardiaCardiac disorders | 0/210 | 5/208 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 5/210 | 1/208 |
| Vascular stent stenosisGeneral disorders | 5/210 | 3/208 |
| Coronary artery diseaseCardiac disorders | 2/210 | 4/208 |
| Event | SELUTION SLR 014 DEB | Standard Of Care |
|---|---|---|
| Angina pectorisCardiac disorders | 19/210 | 19/208 |
| Chest painGeneral disorders | 11/210 | 6/208 |
The primary analysis population is Per Protocol. The Per Protocol population is 197 participants for the SELUTION SLR 014 DEB group and 193 participants for the Standard of Care group.
| Age, Continuous(Years) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Median | 68 (63 to 75) | 71 (63 to 76) | 69 (63 to 75) |
| Sex: Female, Male(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Female | 36 | 50 | 86 |
| Male | 161 | 143 | 304 |
| Ethnicity (NIH/OMB)(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 9 | 15 | 24 |
| Not Hispanic or Latino | 137 | 145 | 282 |
| Unknown or Not Reported | 51 | 33 | 84 |
| Diabetes(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Count of participants | 85 | 82 | 167 |
| Hypertension(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Count of participants | 183 | 180 | 363 |
| Hypercholesterolemia(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Count of participants | 179 | 171 | 350 |
| Prior Myocardial Infarction (MI)(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Count of participants | 94 | 93 | 187 |
| Current smoker(Participants) | SELUTION SLR 014 DEB | Standard Of Care | Total |
|---|---|---|---|
| Count of participants | 30 | 27 | 57 |
8 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2020 to primary completion in Aug 2025, 61 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Of 13 interventional studies with no phase under Coronary Restenosis, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 61. This study's 61 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
M.A. Med Alliance S.A.